Cargando…
Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma
Pancreatic adenocarcinoma (PAAD) has high mortality and a very poor prognosis. Both surgery and chemotherapy have a suboptimal therapeutic effect, and this caused a need to find new approaches such as immunotherapy. Therefore, it is essential to develop a new model to predict patient prognosis and f...
Autores principales: | Dai, Lei, Mugaanyi, Joseph, Cai, Xingchen, Lu, Caide, Lu, Changjiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279485/ https://www.ncbi.nlm.nih.gov/pubmed/35831362 http://dx.doi.org/10.1038/s41598-022-16155-w |
Ejemplares similares
-
Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model
por: Dai, Lei, et al.
Publicado: (2022) -
Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2021) -
A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas
por: Dai, Lei, et al.
Publicado: (2022) -
Undifferentiated Pancreatic Carcinomas, Clinical Features and Therapeutic Options: What We Know
por: Mugaanyi, Joseph, et al.
Publicado: (2022) -
Extended pancreato-duodenectomy coupled with adjuvant chemotherapy for SMARCB1/INI1 deficient pancreatic carcinoma: A case report and literature review
por: Mugaanyi, Joseph, et al.
Publicado: (2021)